Cutaneous effects of BRAF inhibitor therapy: A case series

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 530-537

  Mattei, P L ^a   Alora Palli, M B ^a   Kraft, S ^a   Lawrence, D P ^a   Flaherty, K T ^a   Kimball, A B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

BRAF inhibitor; Cutaneous squamous cell carcinoma; MEK inhibitor; Photosensitivity; Side effects

Indexed keywords

DABRAFENIB; GSK 112021; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CASE STUDY; CLINICAL ARTICLE; CLINICAL EVALUATION; COLON CANCER; CRYOTHERAPY; CYST; DRUG EFFECT; DRUG INDICATION; DRUG SAFETY; ERYTHEMA NODOSUM; FEMALE; FOLLOW UP; GENITAL HERPES; HAND FOOT SYNDROME; HUMAN; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG CARCINOMA; MALE; MEDICAL RECORD REVIEW; MELANOMA; METASTATIC MELANOMA; MILIUM; NEVUS; PAPULAR RASH; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PUSTULE; SALIVARY GLAND CANCER; SKIN CARCINOMA; SKIN DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; URTICARIA; VERRUCA VULGARIS;

EID: 84873876998     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds292     Document Type: Article

References (46)

1. Davies H, Bignell GR, Cox C et al Mutations of the BRAF gene in human cancer. Nature 2002; 417(6892): 949-954.
2. Dummer R, Robert C, Chapman PB et al AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, phase II study. J Clin Oncol 2008; 26(Suppl): (Abstr 9033).
3. Wan PT, Garnett MJ, Roe SM et al Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116(6): 855-867.
4. Chapman PB, Hauschild A, Robert C et al Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364(26): 2507-2516.
5. Wellbrock C, Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010; 80(5): 561-567.
6. Zelboraf [package insert]. San Francisco, CA: Genentech Inc. 2011.
7. Williams VL, Cohen PR, Stewart DJ. Sorafenib-induced premalignant and malignant skin lesions. Int J Dermatol 2011; 50(4): 396-402.
8. Kwon EJ, Kish LS, Jaworsky C. The histologic spectrum of epithelial neoplasms induced by sorafenib. J Am Acad Dermatol 2009; 61(3): 522-527.
9. Trefzer U, Minor D, Ribas A et al BREAK-2: A phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF (V600E/K) mutation-positive metastatic melanoma. In 8th International Congress of the Society for Melanoma Research, Tampa, Florida, 2011.
10. Flaherty KT, Puzanov I, Kim KB et al Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363(9): 809-819.
11. Ribas A, Kim KB, Schuchter LM et al BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutationpositive metastatic melanoma. J Clin Oncol 2011; 29(Suppl): (Abstr 8509).
12. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005; 26(10): 1657-1667.
13. Giglia-Mari G, Sarasin A. TP53 mutations in human skin cancers. Hum Mutat 2003; 21(3): 217-228.
14. Noor R, Trinh V, Kim K et al. BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety. Clin Invest 2011; 1(8): 1127-1139.
15. Su F, Viros A, Milagre C et al RAS mutations in cutaneous squamous cell carcinomas with BRAF inhibitors. N Engl J Med 2012; 366(3): 207-215.
16. Majewski S, Jablonska S. Skin autografts in epidermodysplasia verruciformis: human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion. Cancer Res 1997; 57(19): 4214-4216.
17. Harwood CA, Surentheran T, McGregor JM et al Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000; 61(3): 289-297.
18. Purdie KJ, Sexton CJ, Proby CM et al Malignant transformation of cutaneous lesions in renal allograft patients: a role for human papillomavirus. Cancer Res 1993; 53(21): 5328-5333.
19. Berkhout RJ, Tieben LM, Smits HL et al. Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol 1995; 33 (3): 690-695.
20. de Villiers EM. Papillomavirus and HPV typing. Clin Dermatol 1997; 15(2): 199-206.
21. Shamanin V, Zur Hausen H, Lavergne D et al Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst 1996; 88(12): 802-811.
22. Tieben LM, Berkhout RJ, Smits HL et al Detection of epidermodysplasia verruciformis-like human papillomavirus types in malignant and premalignant skin lesions of renal transplant recipients. Br J Dermatol 1994; 131(2): 226-230.
23. Riddel C, Rashid R, Thomas V. Ungual and periungual human papillomavirusassociated squamous cell carcinoma: a review. J Am Acad Dermatol 2011; 64(6): 1147-1153.
24. Iftner A, Klug SJ, Garbe C et al The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res 2003; 63 (21): 7515-7519.
25. Asgari MM, Kiviat NB, Critchlow CW et al Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol 2008; 128(6): 1409-1417.
26. Heidorn SJ, Milagre C, Whittaker S et al Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140(2): 209-221.
27. Hatzivassiliou G, Song K, Yen I et al RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464(7287): 431-435.
28. Poulikakos PI, Zhang C, Bollag G et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464(7287): 427-430.
29. Zhang YL, Keng YF, Zhao Y et al. Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases. J Biol Chem 1998; 273(20): 12281-7.
30. Kobayashi K, Pezen DS, Vogelzang NJ et al Keratoacanthomas and skin neoplasms associated with suramin therapy. Arch Dermatol 1996; 132(1): 96-98.
31. Kenner JR, Sperling LC, Waselenko J et al. Suramin keratosis: a unique skin eruption in a patient receiving suramin for metastatic prostate cancer. J Urol 1997; 158(6): 2245-2246.
32. Dubauskas Z, Kunishige J, Prieto VG et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009; 7(1): 20-23.
33. Escudier B, Eisen T, Stadler WM et al Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125-134.
34. Huang V, Hepper D, Anadkat M et al. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol 2012; 148(5): 628-633.
35. Infante JR, Falchook GS, Lawrence DP et al Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 2011; 29(Suppl): (Abstr CRA8503).
36. James WD, Berger TG, Elston DM et al. Andrews' Diseases of the Skin: Clinical Dermatology, 10th edition. Philadelphia: Saunders Elsevier 2006.
37. Forslund O, Ly H, Reid C et al. A broad spectrum of human papillomavirus types is present in the skin of Australian patients with non-melanoma skin cancers and solar keratosis. Br J Dermatol 2003; 149(1): 64-73.
38. Ho GY, Burk RD, Fleming I et al. Risk of genital human papillomavirus infection in women with human immunodeficiency virus-induced immunosuppression. Int J Cancer 1994; 56(6): 788-792.
39. Giampieri S, Storey A. Repair of UV-induced thymine dimers is compromised in cells expressing the E6 protein from human papillomaviruses types 5 and 18. Br J Cancer 2004; 90(11): 2203-2209.
40. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: Insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004; 109(2): 157-162.
41. Comin-Anduix B, Chodon T, Sazegar H et al The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res 2010; 16(24): 6040-6048.
42. Johnson TM, Rowe DE, Nelson BR et al. Squamous cell carcinoma of the skin (excluding lip and oral mucosa). J Am Acad Dermatol 1992; 26(3 Pt 2): 467-484.
43. Berk DR, Bayliss SJ. Milia: a review and classification. J Am Acad Dermatol 2008; 59(6): 1050-1063.
44. Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol 2011; 9(1): 13-23.
45. Pomerantz RG, Mirvish ED, Geskin LJ. Cutaneous reactions to epidermal growth factor receptor inhibitors. J Drugs Dermatol 2010; 9(10): 1229-1234.
46. Balagula Y, Barth Huston K, Busam KJ et al. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 2011; 29(5): 1114-1121.